Last reviewed · How we verify
Dapsone Topical Gel + vehicle control
Dapsone Topical Gel + vehicle control is a Sulfone antimicrobial and anti-inflammatory agent Small molecule drug developed by Allergan. It is currently in Phase 3 development for Acne vulgaris.
Dapsone is a sulfone antimicrobial and anti-inflammatory agent that inhibits bacterial folate synthesis and suppresses neutrophil function to reduce inflammation in acne.
Dapsone is a sulfone antimicrobial and anti-inflammatory agent that inhibits bacterial folate synthesis and suppresses neutrophil function to reduce inflammation in acne. Used for Acne vulgaris.
At a glance
| Generic name | Dapsone Topical Gel + vehicle control |
|---|---|
| Sponsor | Allergan |
| Drug class | Sulfone antimicrobial and anti-inflammatory agent |
| Target | Dihydropteroate synthase; neutrophil function modulation |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Dapsone acts through dual mechanisms: it inhibits dihydropteroate synthase in bacteria, disrupting folate metabolism, and also suppresses neutrophil chemotaxis and oxidative burst, reducing inflammatory responses in acne lesions. When formulated as a topical gel, it delivers these anti-inflammatory and antimicrobial effects directly to affected skin with minimal systemic absorption.
Approved indications
- Acne vulgaris
Common side effects
- Erythema
- Dryness
- Peeling
- Contact dermatitis
Key clinical trials
- Randomized, Triple-Blind, Placebo-Controlled Trial of Topical Dapsone Gel in Patients With Acne Vulgaris (PHASE4)
- Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris (PHASE1)
- Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris (PHASE1)
- Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris (PHASE3)
- A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG) Twice Daily in Combination With Once Daily Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4% (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dapsone Topical Gel + vehicle control CI brief — competitive landscape report
- Dapsone Topical Gel + vehicle control updates RSS · CI watch RSS
- Allergan portfolio CI
Frequently asked questions about Dapsone Topical Gel + vehicle control
What is Dapsone Topical Gel + vehicle control?
How does Dapsone Topical Gel + vehicle control work?
What is Dapsone Topical Gel + vehicle control used for?
Who makes Dapsone Topical Gel + vehicle control?
What drug class is Dapsone Topical Gel + vehicle control in?
What development phase is Dapsone Topical Gel + vehicle control in?
What are the side effects of Dapsone Topical Gel + vehicle control?
What does Dapsone Topical Gel + vehicle control target?
Related
- Drug class: All Sulfone antimicrobial and anti-inflammatory agent drugs
- Target: All drugs targeting Dihydropteroate synthase; neutrophil function modulation
- Manufacturer: Allergan — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Acne vulgaris
- Compare: Dapsone Topical Gel + vehicle control vs similar drugs
- Pricing: Dapsone Topical Gel + vehicle control cost, discount & access